Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN17109689
ISRCTN17109689
Completed
Not Applicable

Effects on progression of renal failure and nutritional status by correction of metabolic acidosis in patients with non-dialysis dependent chronic kidney disease (CKD)

Barts and the London NHS Trust (UK)0 sites134 target enrollmentJanuary 18, 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Barts and the London NHS Trust (UK)
Enrollment
134
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 18, 2008
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Barts and the London NHS Trust (UK)

Eligibility Criteria

Inclusion Criteria

  • •1\. Age greater than 18 years old
  • •2\. CKD stage 4 and 5
  • •3\. Mild to moderate metabolic acidosis (serum bicarbonate less than 21 and greater than 16 mmol/L) on two consecutive measurements
  • •4\. Stable clinical condition

Exclusion Criteria

  • •Patients with:
  • •1\. Malignant disease
  • •2\. Morbid obesity
  • •3\. Cognitive impairment
  • •4\. Chronic sepsis
  • •5\. Poorly controlled blood pressure (greater than 150/90 mmHg), despite use of four agents
  • •6\. Overt congestive heart failure

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Influence of renal dysfunction on the outcomes of hepatectomy for hepatocellular carcinoma
JPRN-UMIN000041749Hiroshima University238
Completed
Not Applicable
Effect of continuous nutritional guidance on renal protection of chronic kidney disease patients before dialysisChronic renal failure
JPRN-UMIN000034636Saitama Tsukinomori Clinic100
Completed
Not Applicable
The effect of varying degrees of renal impairment on the single dose pharmacokinetic profile of orally administered lurasidone: a phase I studyRenal impairmentUrological and Genital Diseases
ISRCTN16720571Dainippon Sumitomo Pharma Europe Ltd (UK)33
Recruiting
Not Applicable
Examination of the effects on renal function and prognosis of various diuretics for liver cirrhosisiver cirrhosis
JPRN-UMIN000040179Hokkaido University400
Active, not recruiting
Phase 1
Evaluation of the impact of renal function on the pharmacokinetics of hydroxyurea (Siklos®) in patients with sickle cell disease with normal renal function, with hyperfiltration, or with renal failure. DARH studySiklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years suffering from symptomatic sickle cell syndrome.MedDRA version: 17.1Level: LLTClassification code 10040643Term: Sickle cell crisisSystem Organ Class: 100000004851Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2014-005033-31-FRAddmedica S.A.S